Search clinical trials for: AML from MDS

Total 14489 results

National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | MDS (Myelodysplastic Syndrome) | CML (Chronic Myelogenous Leukemia) | AML (Acute Myelogenous Leukemia)

United States
University of Wisconsin, Madison

Terminated

FLT-PET Imaging for MDS

AML | MDS

United States
Carlos Graux, MD, PhD
Celgene Corporation; Belgian Hematological Society

Completed

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Belgium
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Anemia With Excess Blasts

United States
Washington University School of Medicine
Cantex Pharmaceuticals

Completed

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes | AML | MDS

United States
Stanford University

Completed

Allogeneic Transplantation From Related Haploidentical Donors

Leukemia | MDS | NHL | Graft Versus Host Disease | Blood Cancer | Malignancy | CLL | Hodgkin's Disease

United States
Boston Children's Hospital

Completed

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

AML | ALL | Biphenotypic Leukemia | Refractory Anemia | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts | Undifferentiated Leukemia | Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts | Refractory Anemia With Excess Blasts-1 (5-10% Blasts) | Refractory... and other conditions

United States
Celgene

Completed

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function (RENAL)

Multiple Myeloma | Non-Hodgkin's Lymphoma | AML | Solid Tumors | MDS | Hodgkin's Disease

United States
Celgene

Completed

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry (MORE)

Myelodysplastic Syndrome

Italy
Fred Hutchinson Cancer Center
Patient-Centered Outcomes Research Institute; American Cancer Society, Inc.

Completed

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Celgene

Completed

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
Celgene

Completed

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (RACE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Leukemia, Myelomonocytic, Chronic

United States
Van Andel Research Institute

Completed

Ascorbic Acid Levels in MDS, AML, and CMML Patients

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML

United States
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Acute Leukaemia

United States, Belgium, Canada, Australia, Greece, Israel, Russian Federation, Hungary, Korea, Republic of, Poland
Second Affiliated Hospital of Wenzhou Medical University

Unknown

A Bioequivalence Study of Valsartan / Amlodipine From Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerland) (ABSVAFVATVAT)

Healthy

China
Pfizer

No longer available

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (AML)

CD33 Positive Acute Myelogenous Leukemia

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Unknown

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Asan Medical Center

Terminated

Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS (DNKI-4)

Acute Myelogenous Leukemia

Korea, Republic of
Incyte Corporation

Terminated

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Terminated

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Shandong Provincial Hospital

Unknown

A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

Myelodysplastic Syndromes,Acute Myeloid Leukemia

China
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

France, Australia
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Io Therapeutics

Terminated

Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
Novartis Pharmaceuticals

Withdrawn

A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)
PersImmune, Inc
University of California, San Diego

Unknown

Collection of Samples From Patients With MDS

Myelodysplastic Syndromes(MDS)

United States
Spirita Oncology, LLC

Terminated

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

AML | MDS | CMML

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Center for Research Resources (NCRR); Otsuka Pharmaceutical Co., Ltd.

Completed

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

MDS | Lymphomas | Leukemias

United States
Agios Pharmaceuticals, Inc.

Completed

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Myelodysplastic Syndrome | Hematologic Malignancies | Acute Myeloid Leukemia (AML)

United States, France
Institut Curie
National Cancer Institute, France; Fondation ARC

Terminated

PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)

Acute Myeloid Leukemia, in Relapse | Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome | de Novo Acute Myeloid Leukemia at Diagnostic

France
Viron Therapeutics Inc
Vion Pharmaceuticals

Terminated

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Celgene

Completed

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, United Kingdom
Masonic Cancer Center, University of Minnesota
University of Minnesota

Withdrawn

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Treatment-Related Acute Myeloid Leukemia | High-Risk Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia, Myeloid

United States
M.D. Anderson Cancer Center
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center

Terminated

Study of Gelonin Purging of Autologous Stem Cells for Transplantation

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center

Terminated

Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

Leukemia | Aplastic Anemia | Non Hodgkin's Lymphoma

United States
GWT-TUD GmbH

Terminated

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (SAMBA)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

France, Germany
Dartmouth-Hitchcock Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

United States
Michael Luebbert
University Hospital Freiburg

Unknown

Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Celgene

Terminated

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Aeglea Biotherapeutics

Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals; Celgene Corporation

Completed

PKC412 and 5-Azacytidine

Leukemia

United States
Affiliated Hospital to Academy of Military Medical...
Hangzhou ImmuQuad Biotechnologies, LLC

Completed

Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT

Recurrence | Hematologic Neoplasms | Hematopoietic Stem Cell Transplantation | Graft Vs Host Disease

China
M.D. Anderson Cancer Center
Millennium: The Takeda Oncology Company

Terminated

Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission

Leukemia

United States
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

United Kingdom, Germany, Belgium
University Hospital Southampton NHS Foundation...
Genzyme, a Sanofi Company

Completed

Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)

Myelodysplasia | Acute Myeloid Leukaemia

United Kingdom

Search clinical trials for: AML from MDS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations